Wait and see10 Oct 2025 08:15
The study was designed to support longer-term dosing of SDC-1801 and to investigate the molecule's general toxicology. These are key regulatory requirements ahead of the planned Phase 2 clinical development programme, which is expected to focus initially on psoriasis.
A preliminary assessment of the available data indicates that the findings observed during the study were disproportionately present in control-group animals which were not treated with SDC-1801, and based on the information available, are therefore considered highly unlikely to be related to SDC-1801. Sareum is reviewing the study data with the contractor and expert consultants to determine the cause of the findings and the appropriate next steps.
Now if Parker was to put out they are confident it has nothing to do with 1801 we are back on track
Not like me to to be backing up the BOD
Stay calm and and as the day in the Army
Wait Out